

S P E C I F I C A T I O N

TITLE

APPARATUS AND METHOD FOR INACTIVATING  
VIRAL CONTAMINANTS IN BODY FLUIDS

006250 TEST 950

BACKGROUND OF THE INVENTION

5 The present invention relates generally to apparatus and methods for inactivating viral contaminants that may be present in the body fluids. More specifically, the invention relates to apparatus and methods for photodynamically inactivating viral contaminants in body fluids.

10 In a variety of therapies, such as transfusions and transplants, body fluids, especially blood components such as red blood cells, platelets, plasma, leukocytes, and bone marrow, are collected from one or more individuals and then infused into a patient. Although such therapies provide treatments, some of which are life saving, due to the transmission of infectious diseases  
15 there may be potential risks involved with such therapies.

By way of example, it is known that blood can carry infectious agents such as hepatitis virus, human immunodeficiency virus (an etiological agent for AIDS),  
20 and cytomegalovirus. Although screening methods exist to identify blood that may include such viruses, blood containing viruses, and other disease causing pathogens, such as bacteria, cannot be 100% eliminated from the pool of possible blood component supplies. Therefore, there  
25 is still a small risk that blood transfusions can transmit viral or other infections.

Accordingly, a goal of recent biomedical research has been to reduce the risk of transmitting an infectious agent by selectively inactivating or depleting pathogens  
30 present in such blood components. One approach has been to utilize photosensitive (photoactive) agents that when activated by light of the appropriate wavelength will destroy the ability of the pathogen to cause infection.

00675511.092900

5

10

15

25

30

One photoactive agent that appears to be promising with respect to eradicating viruses and bacteria from blood is methylene blue. Methylene blue 3-7-

bis(dimethylamino)phenothiazine-5-ium chloride  
( $C_{16}H_{18}ClN_3S$ ), in the presence of light has been reported  
to damage DNA and generate singlet oxygen which damages  
the virus envelop. Accordingly, it can be used to  
5 selectively, in a controlled manner, modify the DNA and  
RNA of bacterial and viral contaminants thereby  
inactivating the pathogens. See U.S. Patent No.  
4,950,665.

It has recently been determined, however, that if  
10 methylene blue is placed into a standard blood pack unit  
constructed from PVC under standard conditions and the  
unit is then heat sterilized, that at least a certain  
amount of the methylene blue migrates into the PVC layer  
reducing the methylene blue present. The specific amount  
15 of methylene blue that migrates is variable depending  
upon the conditions. However, envisioned methods of  
using methylene blue to treat blood and other body fluids  
require that precise amounts of methylene blue be used.

This unfortunately requires that the blood packs  
20 must be sterilized prior to methylene blue being added  
thereto. This can create logistic problems as well as  
increase the cost of creating the product. Likewise,  
during the methylene blue filling process, there is the  
risk of contaminating the sterilized container.

However, it has recently been discovered that  
25 methylene blue can be housed in certain containers, or  
under certain conditions, and sterilized with the blood  
pack unit without the methylene blue migrating into the  
plastic. It has been found that two of the parameters  
30 that have a great effect on preventing methylene blue  
from migrating into the plastic are: the type of  
plastic; and the pH of the methylene blue solution.

006260" T554950

~~Application Serial No. 07/952,427~~, filed September 28, 1992, the disclosure of which is fully incorporated herein by reference. The housing includes at least an inner surface, the surface that contacts the methylene blue solution, that is constructed from a non-PVC material.

092531

15

20

25

30

In an embodiment of the invention, the body fluid ~~is~~ a blood component.

In an embodiment of the invention, the blood component is selected from the group consisting of: plasma, red blood cells, white blood cells, leukocytes, bone marrow, and platelets.

5 In an embodiment of an invention, the step of forming a mixture comprises the step of adding the methylene blue to a container in which the body fluid is already stored.

10 In an embodiment of the invention, the step of irradiating includes the step of transporting the mixture in the container along a path of a light field.

In an embodiment, the invention provides the further step of allowing excess methylene blue to leach out into the container after the irradiation step.

15 In an embodiment of the invention, the light field is generated by an array of light emitting diodes.

In an embodiment, the invention provides an apparatus for inactivating at least viruses in a body fluid with methylene blue. The apparatus comprises at least one light source disposed along a path of travel and configured to generate a light field on the path of travel with a frequency suitable for activating methylene blue while not adversely effecting body fluids. The apparatus also includes a transport associated with the light source and configured to transport a container enclosing a mixture of the body fluid and a therapeutically effective amount of the methylene blue along the path of travel and within the light field generated by the light source.

20

25

30 In an embodiment of the invention, the light source comprises a light emitting diode.

00675511 092900

In an embodiment of the invention, the light emitting diode light source generates a light field with a wavelength of about 670 nm.

5 In an embodiment of the invention, the light source comprises an array of light emitting diodes.

In an embodiment of the invention, the transport is configured to transport the container within the light field for at least 5 minutes.

10 In an embodiment, the invention provides a method for inactivating viruses in a body fluid, comprising the steps of forming a mixture of the body fluid and an effective amount of methylene blue in a container under sterile conditions; and irradiating a mixture with a light field generated by an array of light emitting  
15 diodes for a duration sufficient to activate the methylene blue such that the mixture can remain substantially static within the container.

20 An advantage of the present invention is to provide a method for inactivating viral contaminants in body fluids.

Additional features and advantages of the present invention are described in, and will be apparent from, the detailed description of the presently preferred embodiments and from the drawings.

25

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 illustrates a perspective view of a device for irradiating a container with a light field.

30 Figure 2 illustrates a fragmentary cross section of the device of Figure 1.

Figure 3 illustrates a system for irradiating a container with a light field and transporting the container through the light field.

00675511 092900

DETAILED DESCRIPTION OF THE  
PRESENTLY PREFERRED EMBODIMENTS

5 The present invention provides apparatus and methods  
for inactivating pathogens that may be contained in the  
body fluids. As used herein, body fluid not only  
includes blood and its components, but also includes  
10 other fluids contained in the body such as blood  
components, leukocytes, red blood cells, white blood  
cells, plasma (even fresh frozen), etc., bone marrow,  
semen, or fluid containing structures such as internal  
organs.

As previously noted, although body fluids, such as  
blood and its components, can be used in many therapeutic  
15 applications, there is the danger of the transfer of  
infectious disease due to viral and bacterial  
contaminants that may be contained in such fluids.  
Recently the use of photoactive agents has provided the  
hope of inactivating viral and bacterial contaminants  
that may be contained in such fluids. However, in order  
20 to commercialize such methods, certain obstacles must be  
overcome.

It is known to house blood components in plastic  
containers. Typically, the plastic container comprises  
a polyvinyl chloride structure that is plasticized with  
25 di(2-ethylhexyl)phthalate (DEHP) and includes  
stabilizers. Blood components are stored particularly  
well in such containers. However, it has been found that  
when a solution of methylene blue, a photoactive agent  
of promise, is placed in such a container at a  
30 physiological pH of around 7, that upon steam  
sterilization, the photoactive agent (methylene blue)  
migrates into the plastic.

Methods of use of methylene blue to inactivate viral contaminants require rather precise amounts of methylene blue. See, for example, Lambrecht, et al., *Photoinactivation of Viruses in Human Fresh Plasma by Phenothiazine Dyes in Combination with Visible Light*, Vox Sang 1991; 60:207-213. Therefore, the migration of the methylene blue solution into the plastic during the sterilization process are believed to provide an unacceptable system.

It has also been found that the migration of methylene blue into the plastic is dependent on a couple of controllable parameters. Therefore, it is possible to provide apparatus and systems wherein methylene blue can be contained within a plastic structure, the structure can be steam sterilized, and the methylene blue solution will be recovered in sufficient quantity to allow the solution to be used to inactivate viral contaminants in a body fluid.

By controlling the type of plastic from which the housing that contains the methylene blue is constructed, the migration of methylene blue into the housing can be controlled. In this regard, it has been found that if at least the layer of the container that contacts the methylene blue is constructed from a non-PVC material, the methylene blue stored therein will not substantially migrate into the plastic.

Although it is envisioned that with proper controls of other parameters, any non-PVC plastic material can be used, of most interest are the more inert plastics, such as polyolefins and polyurethanes. In a preferred embodiment, polypropylene, styrene-ethylene-butylene-styrene (SEBS), ethylenevinyl acetate, and polyesters are used.

By way of example, referring first to Figure 2, a container 10 is illustrated. The container 10 includes ports 12 and 14 extending therefrom to provide access to an interior of the container 10.

5 In the container 10 illustrated, the ports 12 and 14 extend from the container 10 and provide means for infusing the body fluid, such as blood or blood components, into the container 10. An example of a system that can be used is the Optipak® system that is disclosed in U.S. Patent No. 4,608,178. In this system, plasma or red blood cells, for example, can be infused into the container 10 through the ports after having been separated from whole blood.

10 The container 10 can have a structure that is substantially similar to the container for housing blood and blood components available from the Fenwal Division of Baxter International Inc. However, the container 10 can also be constructed so that at least an interior layer that defines the interior surface of the container is constructed from a non-PVC material so as to house methylene blue alone. In that case, most preferably, at least the inner surface of the container 10 is constructed from SEBS, polypropylene, polyester, polyurethane, or ethylenevinyl acetate, or blends thereof. Of course, if desired, the entire container 10 can be constructed from a non-PVC material.

25 Pursuant to the present invention, a body fluid such as a blood component and a therapeutically effective amount of methylene blue are mixed together in the container 10. In one embodiment, the methylene blue is added to body fluid already stored in the container 10. In another embodiment, the body fluid is added to a therapeutically effective amount of methylene blue

already stored in the container 10. The foregoing can be accomplished by any known sterile means and/or method that has been found to function satisfactorily. In this embodiment, the amount of methylene blue solution used is about 10 ml.

It has been found that the pH of the solution can effect the migration of the solution into the plastic material during sterilization. Preferably, the methylene blue solution has been adjusted to a pH of less than 7.0 and most preferably approximately 6.3 or less.

Pursuant to the present invention, if methylene blue solution is initially infused into the container 10, the container 10 and methylene blue solution can then be steam sterilized, e.g., at 115°C for 65 minutes. Due to the use of a methylene blue solution having a pH of less than 7.0 and the fact that the container 10 would then include at least an inner surface that is constructed from a non-PVC material, the methylene blue solution, during steam sterilization, will not substantially migrate into the plastic.

A body fluid, such as a blood component, can then be infused into the container 10 through port 14 or 12. To control fluid flow through the port, a breakable cannula or other means can be used.

In the container 10, the body fluid, preferably a blood component, will mix with the methylene blue solution. The container 10 is then irradiated by a light field of the appropriate wavelength (approximately 620-670 nm) to activate the methylene blue within the container 10. This will cause the methylene blue to inactivate any pathogens, e.g., viruses and bacteria, that are contained within the blood component, thus insuring a blood component that does not contain

pathogens. Preferably, the mixture is inactivated for a sufficiently long period of time and at a suitable wavelength to inactivate at least substantially all the viruses in the mixture.

5 Referring now to both Figures 1 and 2, there is illustrated an apparatus 200 for generating the appropriate light field. As illustrated, the apparatus 200 preferably includes facing arrays 202 and 204 of light emitting diodes 206 that generate the light field  
10 to which the container 10 can be subjected. As will be appreciated, the apparatus 200 preferably is used for activating methylene blue in single units of fresh frozen plasma.

15 In an embodiment of the apparatus 200, the light emitting diodes 206 comprise light emitting diodes manufactured by Hewlett Packard under the designation HLMP-8103 and have a light output centered at a wavelength of about 670 nm. Red blood cells are transparent to light radiated at about this wavelength.  
20 The methylene blue, however, is not. Instead, at this wavelength the methylene blue absorbs the light and becomes activated.

In an embodiment, the light emitting diodes 206 preferably are mounted onto printed circuit boards 211  
25 and 213 about the size of 8½" x 11" sheets of paper. Each board then holds approximately 1280 light emitting diodes forming the relatively large arrays 202 and 204 of light emitting diodes. When powered by a 12 volt DC power supply, the pair 202 and 204 of such arrays can  
30 deliver a light field of about 30.0 mw per centimeter square.

As illustrated, in the apparatus 200, the two arrays 202 and 204 are mounted facing each other in spaced apart

006551 09600

relation in such a way that a gap 208 is present within which a container containing about 250 ml of the body fluid, preferably fresh frozen plasma, and containing about 1  $\mu$ M methylene blue can be placed between the two arrays 202 and 204. The container can then be irradiated for about 5 minutes, which causes the methylene blue therein to inactivate any virus present.

As a result, the methylene blue and body fluid to be treated can be separately collected and sterilized, and then mixed either in the container in which the methylene blue was collected or the container in which the body fluid was collected. Then, the container can be relatively quickly irradiated by the light field generated by the apparatus 200 so that the mixture therein need not be flowed through flow paths and the like past the sources of light.

In an embodiment, the body fluid and methylene blue are contained in a PVC container. Due to the use of a PVC container, excess methylene, i.e., methylene blue that is not activated or necessary for photoinactivation of the viruses, leaches out into the container material. Thus, the body fluid can be relatively quickly treated and excess methylene blue is removed from the body fluid.

As illustrated in Figure 2, a device such as the apparatus 200 can be equipped with light sensors 210 that can measure how much light is being delivered to the container 10 and how much light is being transmitted through the container 10 to control a total dosage of light. To this end, the apparatus can include a microprocessor based computer 212 that monitors the sensors 210 and computes cumulative dosages of light. Once a sufficient dosage is reached, the computer 212 can shut off the light emitting diodes 206.

It can be appreciated that some body fluids and/or containers are more opaque than other fluids and/or containers and that therefore the computer 212 must adjust the irradiation time to accommodate the different light transmissions through the containers due to the differences in opacities of different body fluids.

As illustrated in Figures 1 and 2, in the embodiment illustrated, the apparatus 200 is constructed such that the array 202 is supported within an arm 220 that overhangs a facing support surface 222. The support surface 222 in turn supports or includes the array 204. The overhang 220 is in turn supported by perpendicular wall 223.

Interconnecting lines or cables 224 can be used to interconnect the diodes 206 of the array 202 and the computer 212. Similar lines or cables 226 can be used to interconnect the diodes 206 of the array 204 to the computer 212. In a readily programmable manner, the computer 212 can be used to turn the arrays 202 and 204 off and on as needed.

At the same time, lines or cables can be used to interconnect the sensors 210 in the array 204 with the computer 212. Similarly, lines or cables 229 can be used to interconnect the sensor 210 in the array 202 with the computer 212.

Referring now to Figure 3, it can be seen that a plurality of such apparatus 200 can be placed along a path of travel defined by, in an embodiment, a conveyor 230. A container can be placed on a belt 232 of the conveyor 230 at one end of the conveyor 230 and transported past successive apparatus 200. It can be appreciated that the speed of the belt 232 can be adjusted. Accordingly, each container 10 placed thereon

00675511-092900

would be transported by the series of light field apparatus 200 with such a timing (preferably 5 minutes or so) that at the end of the path of travel, the container 10 will have been subjected to a sufficient dosage of light to virally inactivate the body fluid contained therein.

A suitable power supply 240, e.g., a 12 volt DC power supply, can be coupled to each apparatus 200 as illustrated. Moreover, the conveyor 230 can be provided with suitable drive wheels 242 and 244 at opposite ends thereof, as well as a suitably controllable drive motor 246. A fan 248 is provided for cooling the device.

It can be appreciated that the belt 232 of the conveyor 230 should be sufficiently translucent to allow both arrays 202 and 204 to generate the appropriate light field. If the belt 232 is not sufficiently translucent, then the light field could be cut up to half and then the exposure time would have to be suitably increased.

With reference to Figure 3, it can be appreciated that all of the apparatus 200 can be connected to a single computer, perhaps even only one of the computers 212 such that the single computer monitors the total dosage of light received by each container 10 passing through the light field. The programming necessary to effect the foregoing is minimal and well within the capabilities of one of ordinary skill in the art, and therefore it is believed to not be necessary to set forth such programming herein.

It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the present

0067511-092900

invention and without diminishing its attendant advantages. It is therefore intended that such changes and modifications be covered by the appended claims.

09675511.092900